FDA Approves New Treatment for Prostate Cancer
"The success of TULSA represents a revolution in whole-gland treatment forprostate cancer," said lead author Steven S. Raman, M.D., FASR, FSIR, professor of radiology, urology and surgery at the David Geffen School of Medicine at UCLA. "Prostate cancer is the most common form of cancer ...
In 1982, Schally et al introduced a radically different hormonal therapy for prostate cancer, based on the use of highly potent synthetic agonistic analogues of luteinising hormone-releasing hormone (LHRH) for the treatment of advanced prostate cancer [1], [2], [3], [4], [5]. The isolatio...
Prostate cancer is the most common form of cancer in men in Western countries. There are approximately 1.1 million new cases around the world per year, and approx. 310,000 die from prostate cancer (GLOBOCAN). There was over four times the incidence of prostate cancer in 2017 as in the 195...
CHICAGO, June 4 (Xinhua) -- A combination of two existing prostate cancer therapies could extend lives of men with advanced, high-risk prostate cancer, a study showed. The addition of Zytiga to androgen-deprivation therapy can "significantly" increase overall survival in men with newly diagnosed...
In recent years the pace of research in prostate cancer has increased dramatically. Creative ideas in combination with new and emerging technologies have led to an explosion of discovery. These types of advances in prostate cancer research presage an era of new treatment strategies based on an unde...
Treating those suffering from prostate cancer with radiotherapy on top of regular treatment could extend the life of men with advanced forms of the disease, research has found. One of the largest ever clinical trials into prostate cancer found an 11% increase in the survival rate of some patient...
doi:10.1038/nrurol.2013.232Grivas, Petros D.Keller, Evan T.Nature Reviews UrologyPetros D.Grivas, Evan T.Keller. (2013) Prostate cancer: Radium-223: a new treatment option for bone-metastatic CRPC. Nature Reviews Urology 10 , 630-631 /...
The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. To design a decision-support tool to facilitate evidence-based treatment decisions in clinically localized prostate cancer, as individualized risk assessme... MS Katz,JA Efstathiou,AV D'Amico,... - 《...
For the first time, researchers have discovered that prostate cancer can be killed by targeting a single enzyme, called PI5P4Kα. The findings, published recently in Science Advances, could help address the growing threat of treatment resistance in prost